S12 Ep28: Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
OncLive® On Air - Een podcast door OncLive® On Air
Drs Aldoss and Jabbour discuss an analysis of PhALLCON that support the use of ponatinib monotherapy after TKI/chemotherapy treatment in Ph-positive ALL.
